A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins

The importance of taking into account protein flexibility in drug design and virtual ligand screening (VS) has been widely debated in the literature, and molecular dynamics (MD) has been recognized as one of the most powerful tools for investigating intrinsic protein dynamics. Nevertheless, deciphering the amount of information hidden in MD simulations and recognizing a significant minimal set of states to be used in virtual screening experiments can be quite complicated. Here we present an integrated MD-FLAP (molecular dynamics-fingerprints for ligand and proteins) approach, comprising a pipeline of molecular dynamics, clustering and linear discriminant analysis, for enhancing accuracy and efficacy in VS campaigns. We first extracted a limited number of representative structures from tens of nanoseconds of MD trajectories by means of the k-medoids clustering algorithm as implemented in the BiKi Life Science Suite ( http://www.bikitech.com [accessed July 21, 2015]). Then, instead of applying arbitrary selection criteria, that is, RMSD, pharmacophore properties, or enrichment performances, we allowed the linear discriminant analysis algorithm implemented in FLAP ( http://www.moldiscovery.com [accessed July 21, 2015]) to automatically choose the best performing conformational states among medoids and X-ray structures. Retrospective virtual screenings confirmed that ensemble receptor protocols outperform single rigid receptor approaches, proved that computationally generated conformations comprise the same quantity/quality of information included in X-ray structures, and pointed to the MD-FLAP approach as a valuable tool for improving VS performances.

[1]  Walter Filgueira de Azevedo,et al.  Crystal structure of human purine nucleoside phosphorylase at 2.3A resolution. , 2003, Biochemical and biophysical research communications.

[2]  Erin S. Bolstad,et al.  In pursuit of virtual lead optimization: The role of the receptor structure and ensembles in accurate docking , 2008, Proteins.

[3]  A. Cavalli,et al.  The ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning , 2015, Nature Communications.

[4]  Gabriele Cruciani,et al.  BioGPS: Navigating biological space to predict polypharmacology, off‐targeting, and selectivity , 2015, Proteins.

[5]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[6]  Stefano Alcaro,et al.  GRID-Based Three-Dimensional Pharmacophores II: PharmBench, a Benchmark Data Set for Evaluating Pharmacophore Elucidation Methods , 2012, J. Chem. Inf. Model..

[7]  Heather A Carlson,et al.  Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.

[8]  Ruben Abagyan,et al.  Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..

[9]  Paolo Benedetti,et al.  FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation using the DUD Data Set , 2010, J. Chem. Inf. Model..

[10]  Pietro Cozzini,et al.  Targeting Cystalysin, a Virulence Factor of Treponema denticola‐Supported Periodontitis , 2014, ChemMedChem.

[11]  Oliver Korb,et al.  Potential and Limitations of Ensemble Docking , 2012, J. Chem. Inf. Model..

[12]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[13]  Varsha Gandhi,et al.  Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma , 2006, Expert opinion on investigational drugs.

[14]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[15]  M L Teodoro,et al.  Conformational flexibility models for the receptor in structure based drug design. , 2003, Current pharmaceutical design.

[16]  J. Mccammon,et al.  Accounting for Receptor Flexibility and Enhanced Sampling Methods in Computer‐Aided Drug Design , 2013, Chemical biology & drug design.

[17]  X. Zou,et al.  Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking , 2006, Proteins.

[18]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[19]  Walter Filgueira de Azevedo,et al.  Structural studies of human purine nucleoside phosphorylase: towards a new specific empirical scoring function. , 2008, Archives of biochemistry and biophysics.

[20]  Charles A. Laughton,et al.  Molecular Dynamics Simulations of the Adenosine A2a Receptor in POPC and POPE Lipid Bilayers: Effects of Membrane on Protein Behavior , 2014, J. Chem. Inf. Model..

[21]  L. Beauchamp,et al.  Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase. , 1996, Journal of medicinal chemistry.

[22]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[23]  Luca Mollica,et al.  Kinetics of protein-ligand unbinding via smoothed potential molecular dynamics simulations , 2015, Scientific Reports.

[24]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[25]  T A Krenitsky,et al.  Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. , 1984, The Journal of biological chemistry.

[26]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[27]  R. Nussinov,et al.  Folding funnels, binding funnels, and protein function , 1999, Protein science : a publication of the Protein Society.

[28]  Pietro Cozzini,et al.  Fine tuning of the active site modulates specificity in the interaction of O-acetylserine sulfhydrylase isozymes with serine acetyltransferase. , 2013, Biochimica et biophysica acta.

[29]  G. Cruciani,et al.  Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. , 2004, Journal of medicinal chemistry.

[30]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[31]  A. Ammann,et al.  NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY , 1975, The Lancet.

[32]  William Sinko,et al.  Applying Molecular Dynamics Simulations to Identify Rarely Sampled Ligand-bound Conformational States of Undecaprenyl Pyrophosphate Synthase, an Antibacterial Target , 2011, Chemical biology & drug design.

[33]  F. J. Luque,et al.  Protein flexibility and ligand recognition: challenges for molecular modeling. , 2011, Current topics in medicinal chemistry.

[34]  R. Abagyan,et al.  Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening , 2011, PloS one.

[35]  Woody Sherman,et al.  Improving database enrichment through ensemble docking , 2008, J. Comput. Aided Mol. Des..

[36]  Massimiliano Bonomi,et al.  PLUMED 2: New feathers for an old bird , 2013, Comput. Phys. Commun..

[37]  X. Barril,et al.  Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. , 2005, Journal of medicinal chemistry.

[38]  Ruben Abagyan,et al.  Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. , 2009, Journal of medicinal chemistry.

[39]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[40]  V. Schramm,et al.  Enzymatic transition states and transition state analogues. , 2005, Current opinion in structural biology.

[41]  Walter Filgueira de Azevedo,et al.  Structure of human PNP complexed with ligands. , 2005, Acta crystallographica. Section D, Biological crystallography.

[42]  Siavoush Dastmalchi,et al.  Prediction of the Human EP1 Receptor Binding Site by Homology Modeling and Molecular Dynamics Simulation , 2011, Scientia pharmaceutica.

[43]  Francesco L Gervasio,et al.  The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. , 2012, Journal of the American Chemical Society.

[44]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[45]  Giorgio Palù,et al.  Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase , 2012, Proceedings of the National Academy of Sciences.

[46]  S E Ealick,et al.  Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Evans,et al.  Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. , 2003, Journal of medicinal chemistry.

[48]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[49]  G. Keserű,et al.  Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. , 2005, Journal of medicinal chemistry.

[50]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[51]  Andrew S Murkin,et al.  Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase. , 2009, Journal of medicinal chemistry.

[52]  J. Andrew McCammon,et al.  Computer-Aided Identification of Trypanosoma brucei Uridine Diphosphate Galactose 4′-Epimerase Inhibitors: Toward the Development of Novel Therapies for African Sleeping Sickness , 2010, Journal of medicinal chemistry.

[53]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[54]  S. Teague.  Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[55]  W. Im,et al.  Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations , 2007, PloS one.

[56]  I. Kuntz,et al.  Molecular docking to ensembles of protein structures. , 1997, Journal of molecular biology.

[57]  Richard J. Hall,et al.  Protein-Ligand Docking against Non-Native Protein Conformers , 2008, J. Chem. Inf. Model..

[58]  G. Marucci,et al.  A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. , 2008, Current pharmaceutical design.

[59]  V. Schramm,et al.  Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. , 1993, Biochemistry.

[60]  Ruben Abagyan,et al.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles , 2010, J. Comput. Aided Mol. Des..

[61]  György M. Keserü,et al.  Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE against JNK-3 and beta-Secretase , 2006, J. Chem. Inf. Model..

[62]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[63]  F. Bushman,et al.  Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.

[64]  Jonathan W. Essex,et al.  Water Network Perturbation in Ligand Binding: Adenosine A2A Antagonists as a Case Study , 2013, J. Chem. Inf. Model..

[65]  Harald Mauser,et al.  Database Clustering with a Combination of Fingerprint and Maximum Common Substructure Methods. , 2005 .

[66]  Karunesh Arora,et al.  Conformational dynamics in human purine nucleoside phosphorylase with reactants and transition-state analogues. , 2010, The journal of physical chemistry. B.

[67]  Steven C. Almo,et al.  Four generations of transition-state analogues for human purine nucleoside phosphorylase , 2010, Proceedings of the National Academy of Sciences.

[68]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[69]  J. Mccammon,et al.  Computational drug design accommodating receptor flexibility: the relaxed complex scheme. , 2002, Journal of the American Chemical Society.

[70]  Chiquito J. Crasto,et al.  Beyond Modeling: All-Atom Olfactory Receptor Model Simulations , 2012, Front. Gene..

[71]  P. Cozzini.  Target Flexibility: An Emerging Consideration in Drug Discovery and Design , 2009 .

[72]  Doriano Fabbro,et al.  Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia , 2006, Acta crystallographica. Section D, Biological crystallography.

[73]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[74]  Pietro Cozzini,et al.  Isozyme-Specific Ligands for O-acetylserine sulfhydrylase, a Novel Antibiotic Target , 2013, PloS one.

[75]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[76]  T. Robak,et al.  Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. , 2006, Current medicinal chemistry.

[77]  Walter Filgueira de Azevedo,et al.  Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. , 2003, Biochemical and biophysical research communications.

[78]  James Andrew McCammon,et al.  Predictive Power of Molecular Dynamics Receptor Structures in Virtual Screening , 2011, J. Chem. Inf. Model..

[79]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[80]  Jonathan W. Essex,et al.  Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..

[81]  Glaucius Oliva,et al.  Purine nucleoside phosphorylase from Schistosoma mansoni in complex with ribose-1-phosphate , 2010, Journal of synchrotron radiation.

[82]  Marcel L. Verdonk,et al.  Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase , 2002, J. Comput. Aided Mol. Des..

[83]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[84]  John R Engen,et al.  Structure and Dynamic Regulation of Abl Kinases* , 2013, The Journal of Biological Chemistry.

[85]  A. Bzowska,et al.  Calf spleen purine-nucleoside phosphorylase: crystal structure of the binary complex with a potent multisubstrate analogue inhibitor. , 2004, Acta crystallographica. Section D, Biological crystallography.

[86]  J Andrew McCammon,et al.  Discovery of a novel binding trench in HIV integrase. , 2004, Journal of medicinal chemistry.

[87]  George Khelashvili,et al.  Ligand-Dependent Conformations and Dynamics of the Serotonin 5-HT2A Receptor Determine Its Activation and Membrane-Driven Oligomerization Properties , 2012, PLoS Comput. Biol..

[88]  H. Bosshard,et al.  Molecular recognition by induced fit: how fit is the concept? , 2001, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[89]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[90]  Olivier Sperandio,et al.  How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.

[91]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.